search
Back to results

Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes (VDLS)

Primary Purpose

Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Ergocalciferol, placebo
Sponsored by
University of Massachusetts, Worcester
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Children, Adolescents, Adults, Type 2 diabetes, Nonalcoholic fatty liver disease, Vitamin D deficiency

Eligibility Criteria

10 Years - 50 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Children: 10 - 17 years
  2. Adults: 18 - 50 years
  3. Type 2 diabetes > 6 mo duration
  4. 25-hydroxyvitamin D [25(OH)D] level of <20 ng/mL
  5. Hepatic triglyceride content (HTGC) value of >5.6%
  6. HbA1c of > 8%;
  7. Ability to take medication by mouth.

Exclusion Criteria:

  1. Pregnant or lactating women
  2. Mental deficiency (IQ <70)
  3. Chronic liver disease
  4. Disorders of vitamin D metabolism, kidney, or parathyroid disease;
  5. Calcium and/or vitamin D supplementation
  6. Mauriac syndrome
  7. Malabsorption of fat soluble vitamins
  8. Drug toxicity and alcoholism

Sites / Locations

  • University of Massachusetts Medical School

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Vitamin D supplementation

Placebo

Arm Description

Ergocalciferol 50,000 IU per week for 6 weeks, then bi-weekly for 6 mo

Placebo capsules, on capsule per week for 6 weeks, then bi-weekly for 6 mo.

Outcomes

Primary Outcome Measures

Change in hepatic triglyceride content (HTGC)
Change in hepatic triglyceride content (HTGC) as measured by proton magnetic resonance spectroscopy (1H MRS)

Secondary Outcome Measures

Hemoglobin A1c
Change in glycemic control as measured by HbA1c.

Full Information

First Posted
May 5, 2014
Last Updated
January 7, 2017
Sponsor
University of Massachusetts, Worcester
search

1. Study Identification

Unique Protocol Identification Number
NCT02132442
Brief Title
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
Acronym
VDLS
Official Title
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
March 2014 (undefined)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
October 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Massachusetts, Worcester

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is designed to study the effect of vitamin D intake on the severity of fatty liver and poor glucose control in patients with type 2 diabetes and fatty liver disease.
Detailed Description
The prevalence of significantly poor glycemic control marked by a hemoglobin A1c (HbA1c) level of ≥ 9.5% in youth with type 2 diabetes (T2D) is 27% 1 and 24.2% in young adults2. Strategies to improve glycemic control in patients with T2D include lifestyle modification, optimization of therapeutic regimens, and correction of comorbid states that impair glycemic control. However, the role of comorbid states on glycemic control in T2D has not been adequately studied. For example, 70% of patients with T2D have nonalcoholic fatty liver disease (NAFLD)3, a potentially serious form of chronic liver disease 4 in which the triad of the development of lipotoxicity-induced mitochondrial dysfunction, activation of inflammatory pathways, and cytokine generation lead to progressive liver damage5. NAFLD is the leading cause of elevated liver enzymes in the US6, and is diagnosed by either liver biopsy or the detection of a hepatic triglyceride content (HTGC) of >5.6% by proton magnetic resonance spectroscopy (1H MRS)2. Despite the high prevalence of NAFLD in T2D, its potential impact on glycemic control through the impairment of hepatic metabolic processes is unclear. This is important because a crucial step in vitamin D metabolism, the hydroxylation of vitamin D at the 25 position, occurs in the liver. The consequence of NAFLD on this critical step in vitamin D metabolism in patients with T2D, and the impact of the resultant 25-hydroxyvitamin D [25(OH)D] deficiency on glycemic control are not well understood. The rationale for this study is that a clear understanding of the role of vitamin D on the pathogenesis of NAFLD is crucial because vitamin D is a prohormone with potent anti-inflammatory properties that inhibit pro-inflammatory cytokines such as tumor necrosis factor- α (TNF-α), interleukin-6, and the activity of macrophages 2 while upregulating the production of anti-inflammatory cytokine, interleukin-10 2which could potentially reverse the effects of insulin resistance (IR) and oxidative stress, the two key components of the 'double hit model' of the pathogenesis of NAFLD. The 'first hit' involves IR-induced hepatocyte lipid accumulation which increases hepatic vulnerability to the components of the 'second hit': oxidative stress and proinflammatory cytokines, leading to mitochondrial dysfunction, inflammation and fibrosis. The investigators7 previously showed that mild hepatic dysfunction in patients with T2D was associated with a high prevalence (47.5%) of vitamin D deficiency as defined by 25(OH)D level of < 20 ng/mL, as well as poor glycemic control. The investigators further reported a significant inverse relationship between HbA1c and 25(OH)D, and also between 25(OH)D and alanine transaminase. These data suggest that mild hepatic dysfunction could impair vitamin D metabolism and negatively impact glycemic control in patients with T2D. The investigators have also accumulated data 8 to show that 25(OH)D supplementation was associated with a significant reduction in HbA1c in T2D without a significant change in insulin or metformin dose. Histologically, a recent animal study reported significant hepatic steatosis in vitamin D-deficient mice compared to vitamin D-sufficient mice 2.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency
Keywords
Children, Adolescents, Adults, Type 2 diabetes, Nonalcoholic fatty liver disease, Vitamin D deficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vitamin D supplementation
Arm Type
Experimental
Arm Description
Ergocalciferol 50,000 IU per week for 6 weeks, then bi-weekly for 6 mo
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo capsules, on capsule per week for 6 weeks, then bi-weekly for 6 mo.
Intervention Type
Dietary Supplement
Intervention Name(s)
Ergocalciferol, placebo
Other Intervention Name(s)
Vitamin D, Placebo
Intervention Description
Ergocalciferol 50000 IU capsules Microcrystalline cellulose
Primary Outcome Measure Information:
Title
Change in hepatic triglyceride content (HTGC)
Description
Change in hepatic triglyceride content (HTGC) as measured by proton magnetic resonance spectroscopy (1H MRS)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Hemoglobin A1c
Description
Change in glycemic control as measured by HbA1c.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children: 10 - 17 years Adults: 18 - 50 years Type 2 diabetes > 6 mo duration 25-hydroxyvitamin D [25(OH)D] level of <20 ng/mL Hepatic triglyceride content (HTGC) value of >5.6% HbA1c of > 8%; Ability to take medication by mouth. Exclusion Criteria: Pregnant or lactating women Mental deficiency (IQ <70) Chronic liver disease Disorders of vitamin D metabolism, kidney, or parathyroid disease; Calcium and/or vitamin D supplementation Mauriac syndrome Malabsorption of fat soluble vitamins Drug toxicity and alcoholism
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benjamin U Nwosu, MD
Organizational Affiliation
University of Massachusetts, Worcester
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Massachusetts Medical School
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01609
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes

We'll reach out to this number within 24 hrs